A move toward more individualized treatment of hyperglycemia is coming in the next American Diabetes Association/European Association for the Study of Diabetes Consensus Report, according to John B. Buse, MD, PhD, cochair of the committee writing the new consensus statement.
He will present a draft of the statement on the management of hyperglycemia in type 2 diabetes at the ADA’s annual scientific sessions in Orlando.
When finalized – after revisions based on comments and feedback from diabetes care providers – clinical researchers, patient groups, payers, regulators, and stakeholders – the statement will update the last revision, issued in 2015.
“We are taking a new look at hyperglycemia based on the many studies conducted since 2014, particularly the cardiovascular outcomes trials,” Dr. Buse, the Verne S. Caviness Distinguished Professor in the division of endocrinology and metabolism and chief of endocrinology at the University of North Carolina, Chapel Hill, said in a statement.
But it’s a good bet that ADA scientific sessions attendees will see a move toward more specific recommendations based on patient characteristics and fewer one-size-fits-all recommendations. Specific characteristics like obesity, cardiovascular disease, and chronic kidney disease will likely be addressed in the new consensus statement.
One aspect of patient care that will see more attention in the ultimate statement is personalized care. “We will certainly highlight the need to individualize all aspects of care in a patient-centered way, taking into account both specific patient attributes and preferences,” Dr. Buse said.
The draft statement will be presented on Tuesday, June 26, at 8:00 a.m., so it may be worth staying for that last day of the meeting.
The final draft of the new statement will be released in October at the EASD annual meeting in Berlin, noted Dr. Buse, also director of the diabetes center at the university.